How Selective RET Inhibitors Work: Selpercatinib and Pralsetinib
RET can be activated in cancer by gene fusions (mostly in lung cancer) or by point mutations (medullary thyroid cancer). Selpercatinib and pralsetinib are inhibitors designed specifically for RET, which distinguishes them from the older multikinase inhibitors that hit RET only as one of many targets.
Quick Answer
RET can be activated in cancer by gene fusions (mostly in lung cancer) or by point mutations (medullary thyroid cancer). Selpercatinib and pralsetinib are inhibitors designed specifically for RET, which distinguishes them from the older multikinase inhibitors that hit RET only as one of many targets.
Side-by-side comparison
Selpercatinib and pralsetinib are both selective RET inhibitors; the differences are in administration and toxicity emphasis rather than mechanism.
| Feature | Selpercatinib | Pralsetinib |
|---|---|---|
| Dosing | Twice daily, by body weight | Once daily, on an empty stomach |
| Blood pressure | Hypertension common, monitored | Hypertension common, monitored |
| Lung | Pneumonitis uncommon | Pneumonitis a recognised risk |
| Blood counts | Less prominent | Neutropenia, anaemia and thrombocytopenia notable |
| Other monitoring | QT interval, liver enzymes | Liver enzymes |
Two Ways RET Is Activated
A RET fusion joins the RET kinase domain to a partner that forces dimerisation and constant activity; these occur in about 1-2% of non-small-cell lung cancers and some thyroid and other cancers. A RET point mutation (for example M918T) activates the receptor directly and is the classic driver of medullary thyroid cancer, sporadic and hereditary.
Both mechanisms leave the RET kinase signalling continuously through RAS-MAPK and PI3K-AKT.
Why 'Selective' Matters
Older drugs such as cabozantinib and vandetanib inhibit RET but also VEGFR2 and other kinases, so their dose is limited by hypertension, bleeding, hand-foot syndrome and other off-target effects, and RET coverage is incomplete.
Selpercatinib and pralsetinib were built to inhibit RET potently while largely sparing VEGFR2. This allows fuller target inhibition at a tolerable dose, better response rates, and meaningful central nervous system activity.
Activity
In the registration trials (LIBRETTO-001 for selpercatinib, ARROW for pralsetinib), overall response rates in RET fusion-positive lung cancer were roughly 60-85% depending on prior treatment, with durable responses and intracranial activity. Response rates in RET-mutant medullary thyroid cancer were also high.
As with other targeted drugs, these are trial populations selected by a validated RET test; the exact alteration and clinical context still matter.
Resistance
On-target resistance includes RET solvent-front mutations (G810C/S/R) that impair drug binding. Off-target resistance through MET amplification, KRAS or BRAF alterations, and acquired fusions has been reported.
Next-generation RET inhibitors intended to cover solvent-front mutations are in development.
Dosing and Monitoring
Both are oral. Selpercatinib is dosed twice daily by body weight; pralsetinib is dosed once daily and its absorption is affected by food, so it is taken on an empty stomach. Both interact with CYP3A modulators and with acid-reducing drugs.
Monitoring across the class covers blood pressure, since treatment-emergent hypertension is common, and liver enzymes, and — because RET inhibition impairs wound healing — a pause around planned surgery. Pralsetinib additionally requires attention to blood counts and to any new respiratory symptoms because of the pneumonitis signal, while QT-interval checks are standard with selpercatinib.
Key Takeaways
- ·RET is activated by fusions (mostly lung) or point mutations (medullary thyroid); both drive constant kinase signalling.
- ·Selpercatinib and pralsetinib inhibit RET selectively, sparing VEGFR2 and improving tolerability and CNS reach.
- ·RET solvent-front mutations and bypass pathways such as MET drive resistance.
Frequently asked questions
How is 'selective' RET inhibition different from older drugs?
Multikinase inhibitors such as cabozantinib and vandetanib hit RET alongside VEGFR2 and other kinases, so dose is limited by off-target effects and RET coverage is incomplete. Selpercatinib and pralsetinib inhibit RET potently while largely sparing VEGFR2.
Do selective RET inhibitors treat both fusions and point mutations?
Yes. RET fusions drive a subset of lung and thyroid cancers and RET point mutations such as M918T drive medullary thyroid cancer; both leave the kinase constantly active and both respond.
What causes resistance to selpercatinib or pralsetinib?
On-target RET solvent-front mutations such as G810C/S/R impair drug binding; off-target routes include MET amplification and acquired RAS or BRAF alterations.
References
- 1Selpercatinib. National Cancer Institute, 2026. NCI
- 2FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions. Clin Cancer Res, 2020. PubMed
- 3RET rearrangements in non-small cell lung cancer: evolving treatment landscape and future challenges. Biochim Biophys Acta Rev Cancer, 2022. PubMed
Continue Reading
ALK Inhibitor Generations Compared: Crizotinib to Lorlatinib
3 min read
How Larotrectinib and Entrectinib Work: TRK Fusion Inhibitors
4 min read
RET Alterations in Cancer: Fusions and Activating Mutations
3 min read
Gene Fusion Testing: FISH, Immunohistochemistry, DNA and RNA Sequencing
3 min read
EGFR Inhibitor Generations Compared: First, Second and Third
4 min read
How Alpelisib Works: Targeting the PI3K Alpha Isoform
3 min read
Choose your next research step
Move from this explanation into a gene profile, a pathway map, or the next evidence update.